Detalhe da pesquisa
1.
Phase and context shape the function of composite oncogenic mutations.
Nature
; 582(7810): 100-103, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32461694
2.
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 566(7745): E11-E12, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30755741
3.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 554(7691): 189-194, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29420467
4.
Molecular mechanisms of assembly and TRIP13-mediated remodeling of the human Shieldin complex.
Proc Natl Acad Sci U S A
; 118(8)2021 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33597306
5.
UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth.
Proc Natl Acad Sci U S A
; 118(31)2021 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34330832
6.
Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer.
Breast Cancer Res Treat
; 199(1): 13-23, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36913051
7.
Pancreatoblastomas and mixed and pure acinar cell carcinomas share epigenetic signatures distinct from other neoplasms of the pancreas.
Mod Pathol
; 35(7): 956-961, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34969956
8.
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.
Nature
; 518(7538): 240-4, 2015 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-25409150
9.
Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.
Proc Natl Acad Sci U S A
; 115(11): E2594-E2603, 2018 03 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-29476008
10.
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.
Int J Cancer
; 145(3): 748-762, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30694565
11.
Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas.
Proc Natl Acad Sci U S A
; 113(11): 3030-5, 2016 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26929372
12.
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis.
J Cell Biochem
; 119(6): 4287-4292, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29345357
13.
How a new drug is born.
Eur Heart J
; 42(32): 3039-3041, 2021 08 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33718951
14.
Quantification of HER family receptors in breast cancer.
Breast Cancer Res
; 17: 53, 2015 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25887735
15.
Biomarkers of drugs targeting HER-family signalling in cancer.
J Pathol
; 232(2): 219-29, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24105684
16.
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.
Proc Natl Acad Sci U S A
; 108(9): 3761-6, 2011 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21321214
17.
Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.
Cell Rep
; 43(5): 114174, 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38700982
18.
Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations.
Clin Cancer Res
; 29(6): 1125-1136, 2023 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36595567
19.
The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation.
Cancer Res
; 82(12): 2269-2280, 2022 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35442400
20.
High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer.
Clin Cancer Res
; 28(1): 137-149, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34593528